Abstract
This article is a response to “comment on ‘Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma’” by Gopal Sharma. With this comment, author highlighted the strengths and limitations of the study. With this response, we respond to this and make a comparison of the results and conclusions.
Keywords: Bladder cancer, NMIBC, Xpert BC
We thank Gopal Sharma for his interest and insightful comments [1] on our published work [2]. The article seeks to make a pooled analysis of Xpert bladder cancer (Xpert BC) based on the five mRNAs for rapid diagnosis of bladder carcinoma, compared with cystoscopy and/or biopsy. In terms of clinical application prospects, Xpert BC is supposed to be used for tumor recurrences and the screening of patients with hematuria. Therefore, samples of hematuria patients were included in this study. However, due to the small number of hematuria patients, the study mainly included the patients with bladder cancer on follow-up. Consequently, the conclusion is more suitable for the follow-up of bladder cancer patients. We agree that Gopal Sharma’s suggestions are reasonable and find that Sharma et al. also pool the data regarding the diagnostic performance of Xpert BC in patients with non-muscle invasive bladder cancer (NMIBC) [3]. The data of hematuria patients in the studies of Valenberg et al. [4] and Wallace et al. [5] were excluded, and 5 more articles from the updated literature search were added by Sharma et al.
The pooled sensitivity and specificity of Xpert BC in the diagnosis of bladder cancer were 0.71 and 0.81 in our research, which is little different from the sensitivity (0.73) and specificity (0.77) of Sharma et al. All articles used cystoscopy and/or biopsy as the gold standard, and the included studies did not get enough data for subgroup analysis of the gold standard, which is consistent with Sharma et al. Besides, our conclusions on the diagnostic performance of Xpert BC in follow-up patients are consistent with Sharma et al.; Xpert BC has acceptable diagnostic accuracy in monitoring patients with NMIBC. And the diagnostic accuracy of high-grade tumors was higher than that of low-grade tumors in subgroup analysis.
Our research still has limitations caused by factors such as heterogeneity. More studies in the future are supposed to contribute to subgroup analysis and heterogeneity resolution.
Acknowledgements
None.
Abbreviations
- Xpert BC
Xpert bladder cancer
- NMIBC
Non-muscle-invasive bladder cancer
Authors’ contributions
YFX and YLL were involved in the writing and editing of the article. The article was revised by XGG. The authors read and approved the final manuscript.
Funding
None.
Availability of data and materials
All data analyzed during this study are included in this published article.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Sharma G. Comment on “Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma”. World J Surg Oncol. 2021;19:237. doi: 10.1186/s12957-021-02359-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Liu YL, Wang XL, Yang XH, Wu XH, He GX, Xie LM, et al. Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma. World J Surg Oncol. 2021;19:42. doi: 10.1186/s12957-021-02154-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sharma G, Sharma A, Krishna M, Devana SK, Singh SK. Xpert bladder cancer monitor in surveillance of bladder cancer: systematic review and meta-analysis. Urol Oncol. 2022;40:163 e161–163 e169. doi: 10.1016/j.urolonc.2021.08.017. [DOI] [PubMed] [Google Scholar]
- 4.Valenberg F, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, et al. Validation of an mRNA-based urine test for the detection of bladder cancer in patients with haematuria. Eur Urol Oncol. 2021;4:93–101. doi: 10.1016/j.euo.2020.09.001. [DOI] [PubMed] [Google Scholar]
- 5.Wallace E, Higuchi R, Satya M, McCann L, Sin MLY, Bridge JA, et al. Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection. J Urol. 2018;199:655–662. doi: 10.1016/j.juro.2017.09.141. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data analyzed during this study are included in this published article.